EUVIMEDEUVIMED entdecken
Crossref

From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis

Willeke van Roon-Mom iD, Chantal Ferguson, Annemieke Aartsma-Rus iD

Nucleic Acid Therapeutics · 2023

DOI: 10.1089/nat.2023.0027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2023. Verfasst von Willeke van Roon-Mom und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Dutch Center for RNA Therapeutics, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Oligonucleotides, Antisense. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisOligonucleotides, AntisenseHumansMutationSuperoxide Dismutase-1United StatesUnited States Food and Drug AdministrationDrug ApprovalEndpoint DeterminationOligonucleotides

Substanzen

Oligonucleotides, AntisenseSuperoxide Dismutase-1SOD1 protein, humantofersenOligonucleotides

Autor:innen und Institutionen

  • Department of Human Genetics, Dutch Center for RNA Therapeutics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • RNA Therapeutics Institute, UMass Chan Medical School, Worcester, Massachusetts, USA.

ORCID-Profile: Willeke van Roon-Mom, Annemieke Aartsma-Rus

Zitieren

APA

van Roon-Mom, W., Ferguson, C., & Aartsma-Rus, A. (2023). From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2023.0027

Vancouver

van Roon-Mom W, Ferguson C, Aartsma-Rus A. From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis. Nucleic Acid Therapeutics. 2023. doi:10.1089/nat.2023.0027

BibTeX
@article{vanRoonMom2023,
  author = {van Roon-Mom, Willeke and Ferguson, Chantal and Aartsma-Rus, Annemieke},
  title = {From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis},
  journal = {Nucleic Acid Therapeutics},
  year = {2023},
  doi = {10.1089/nat.2023.0027}
}
Kostenlos starten →